Moderna (MRNA) Is About to Report Tomorrow. Here Is What to Expect
Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past ...
Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Hosted on MSN1d
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
2MRNA : Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Why MRNA Stock Is Retreating
RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...
Yahoo Finance2d
Moderna, Inc. (MRNA)
Moderna (MRNA) shares move higher after reporting mixed fourth quarter results, which included a wider-than-expected profit loss. GameStop (GME) stock also rises following a CNBC report that ...
Moderna: The Good News Isn't Enough
Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...
Yahoo Finance17d
Why MRNA Stock Is Retreating
The analyst cut her price target on MRNA to $51 from $99 ... which MRNA is developing in partnership with Merck (MRK), to lift MRNA stock this year. Ellison's Statement on Potential Cancer ...